Inactive Instrument

Tricida, Inc.

Equities

TCDA

US89610F1012

Biotechnology & Medical Research

Second Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.

February 25, 2023 at 11:00 pm EST

Tricida, Inc. filed a second amended plan of liquidation with related disclosure statement in the US Bankruptcy Court on February 26, 2023. As per the amended plan filed, general unsecured claim are estimated to be in the amount of $14.68 million which shall be recovered 8% i.e., $1.17 million. There are no changes in the treatment of any other claim class or sources of plan funding.

Latest news about Tricida, Inc.

Tricida, Inc. Went Out of Business	23-06-12	CI
First Motion for Exclusivity Period Extension Approved For Tricida, Inc.	23-06-01	CI
Fifth Amended Liquidation Plan Approved for Tricida, Inc.	23-05-23	CI
Fifth Amended Liquidation Plan Filed by Tricida, Inc.	23-05-22	CI
Fourth Amended Liquidation Plan Filed by Tricida, Inc.	23-05-12	CI
First Motion for Exclusivity Period Extension Filed by Tricida, Inc.	23-05-08	CI
North American Morning Briefing : China Data Helps -3-	23-04-18	DJ
North American Morning Briefing : Stock Futures -3-	23-04-11	DJ
Fourth Amended Disclosure Statement Approved for Tricida, Inc.	23-03-27	CI
Fourth Amended Disclosure Statement Filed by Tricida, Inc.	23-03-24	CI
Third Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	23-03-21	CI
Second Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	23-02-25	CI
First Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	23-02-24	CI
Motion for Asset Sale Approved for Tricida, Inc.	23-02-21	CI
Motion for Asset Sale Approved for Tricida, Inc.	23-02-21	CI
Notice of Selection of Successful Bidder Filed for Tricida, Inc.	23-02-16	CI
Notice of Selection of Successful Bidder Filed for Tricida, Inc.	23-02-16	CI
Tricida, Inc. Announces Resignation of David Bonita as Director	23-01-27	CI
Bidding Procedure Approved for Tricida, Inc.	23-01-25	CI
Tricida, Inc.(OTCPK:TCDA.Q) dropped from NASDAQ Composite Index	23-01-23	CI
Top Premarket Gainers	23-01-18	MT
Tricida, Inc.(NasdaqGS:TCDA) dropped from S&P TMI Index	23-01-18	CI
Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	23-01-17	CI
Tricida, Inc. Filed for Bankruptcy	23-01-11	CI
Motion for Asset Sale Filed by Tricida, Inc.	23-01-10	CI

Chart Tricida, Inc.

Duration

Period

More charts

Company Profile

Tricida, Inc. is a pharmaceutical company. The Company is focused on its investigational drug candidate, veverimer (TRC101). TRC101 is a non-absorbed, orally administered polymer designed to treat metabolic acidosis and slow CKD progression by binding and removing acid from the gastrointestinal (GI) tract. Its veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. Veverimer is a single, high molecular weight, crosslinked polyamine molecule. The size of veverimer prevents systemic absorption from the GI tract. The high degree of cross-linking within veverimer limits swelling and the overall volume in the GI tract, with the goal of facilitating GI tolerability. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.89%	42.75B
LONZA GROUP AG	+47.64%	41.61B
MODERNA, INC.	+11.49%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.94%	18.12B
MEDPACE HOLDINGS, INC.	+29.58%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.96%	11.76B
UNITED THERAPEUTICS CORPORATION	+7.69%	11B

Other Biotechnology & Medical Research